HRP20190341T1 - Dijagnosticiranje srčane insuficijencije - Google Patents

Dijagnosticiranje srčane insuficijencije Download PDF

Info

Publication number
HRP20190341T1
HRP20190341T1 HRP20190341TT HRP20190341T HRP20190341T1 HR P20190341 T1 HRP20190341 T1 HR P20190341T1 HR P20190341T T HRP20190341T T HR P20190341TT HR P20190341 T HRP20190341 T HR P20190341T HR P20190341 T1 HRP20190341 T1 HR P20190341T1
Authority
HR
Croatia
Prior art keywords
heart failure
igfbp2
concentration
patient
quantification
Prior art date
Application number
HRP20190341TT
Other languages
English (en)
Inventor
Philippe Rouet
Fatima SMIH-ROUET
Franck Desmoulin
Michel Galinier
Original Assignee
Institut National de la Santé et de la Recherche Médicale (INSERM)
Université Paul Sabatier Toulouse III
Centre Hospitalier Universitaire De Toulouse
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paul Sabatier Toulouse III, Centre Hospitalier Universitaire De Toulouse filed Critical Institut National de la Santé et de la Recherche Médicale (INSERM)
Publication of HRP20190341T1 publication Critical patent/HRP20190341T1/hr

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/416Systems
    • G01N27/447Systems using electrophoresis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848Methods of protein analysis involving mass spectrometry
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4745Insulin-like growth factor binding protein
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/416Systems
    • G01N27/447Systems using electrophoresis
    • G01N27/44704Details; Accessories
    • G01N27/44717Arrangements for investigating the separated zones, e.g. localising zones
    • G01N27/4473Arrangements for investigating the separated zones, e.g. localising zones by electric means
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/32Cardiovascular disorders
    • G01N2800/325Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/50Determining the risk of developing a disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Electrochemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • External Artificial Organs (AREA)
  • Paper (AREA)

Claims (7)

1. Postupak klasificiranja srčane insuficijencije kod pacijenta klasificiranjem srčane insuficijencije prema Njujorškom kardiološkom društvu (NYHA), naznačen time što se navedeni postupak sastoji u koracima mjerenja koncentracije proteina 2 koji veže inzulinu sličan čimbenik rasta (IGFBP2) u uzorku plazme ili mokraće dobivenom iz navedenog pacijenta, gdje se koncentraciju IGFBP2 uspoređuje s klasificiranjem srčane insuficijencije prema NYHA.
2. Postupak dijagnosticiranja srčane insuficijencije kod pacijenta, naznačen time što se sastoji u: i. određivanju koncentracije IGFBP2 u uzorku plazme ili mokraće dobivenom iz navedenog pacijenta; i ii. uspoređivanju navedene koncentracije s kontrolnom vrijednošću.
3. Postupak u skladu s patentnim zahtjevima 1 ili 2, naznačen time što je srčana insuficijencija asimptomatska srčana insuficijencija, kronična srčana insuficijencija ili akutna srčana insuficijencija.
4. Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što se koncentraciju IGFBP2 mjeri kvantificiranjem razine proteina IGFBP2 u uzorku.
5. Postupak u skladu s patentnim zahtjevom 4, naznačen time što se kvantificiranje razine proteina IGFBP2 provodi upotrebom kompleta protutijela usmjerenih protiv IGFBP2.
6. Postupak u skladu s patentnim zahtjevom 4, naznačen time što se kvantificiranje razine proteina IGFBP2 provodi ELISA-om.
7. Postupak u skladu s patentnim zahtjevom 4, naznačen time što se kvantificiranje razine proteina IGFBP2 provodi tehnikom kapilarne elektroforeze s masenom spektroskopijom.
HRP20190341TT 2012-08-09 2019-02-21 Dijagnosticiranje srčane insuficijencije HRP20190341T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12305988 2012-08-09
EP13747847.5A EP2883057B1 (en) 2012-08-09 2013-08-09 Diagnostic of heart failure
PCT/EP2013/066697 WO2014023820A1 (en) 2012-08-09 2013-08-09 Diagnostic of heart failure

Publications (1)

Publication Number Publication Date
HRP20190341T1 true HRP20190341T1 (hr) 2019-05-31

Family

ID=48953397

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20190341TT HRP20190341T1 (hr) 2012-08-09 2019-02-21 Dijagnosticiranje srčane insuficijencije

Country Status (15)

Country Link
US (2) US20150219669A1 (hr)
EP (1) EP2883057B1 (hr)
JP (2) JP6298054B2 (hr)
CY (1) CY1121406T1 (hr)
DK (1) DK2883057T3 (hr)
ES (1) ES2713098T3 (hr)
HR (1) HRP20190341T1 (hr)
HU (1) HUE042708T2 (hr)
LT (1) LT2883057T (hr)
PL (1) PL2883057T3 (hr)
PT (1) PT2883057T (hr)
RS (1) RS58553B1 (hr)
SI (1) SI2883057T1 (hr)
TR (1) TR201902555T4 (hr)
WO (1) WO2014023820A1 (hr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3004891T3 (pl) 2013-06-06 2019-09-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Biomarker ponownej hospitalizacji po niewydolności serca

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060183681A1 (en) * 2005-02-14 2006-08-17 Bio-Rad Laboratories, Inc. Stabilized compositions containing natriuretic peptides
JP4465469B2 (ja) * 2005-02-21 2010-05-19 国立大学法人佐賀大学 循環器病マーカーとしてのインターロイキン13
EP1722232A1 (en) * 2005-05-09 2006-11-15 F.Hoffmann-La Roche Ag Devices and methods for diagnosing or predicting early stage cardiac dysfunctions
US20080166734A1 (en) * 2005-12-21 2008-07-10 David Xing-Fei Deng Genes and methods of using the same for diagnosis and for targeting the therapy of cardiovascular disease
ES2427924T3 (es) 2006-06-30 2013-11-04 Merck Sharp & Dohme Corp. Biomarcador IGFBP2
CN106908603B (zh) 2007-01-25 2019-04-02 霍夫曼-拉罗奇有限公司 Igfbp-7在心力衰竭评估中的用途
EP2310860A1 (en) * 2008-07-30 2011-04-20 INSERM - Institut National de la Santé et de la Recherche Médicale Blood glutathione as a biomarker for screening asymptomatic patients at risk for heart failure
CN105755112B (zh) * 2010-07-14 2019-06-07 视觉科技生物私人有限公司 结肠直肠癌的诊断
CN105044349B (zh) * 2010-08-26 2018-04-06 弗·哈夫曼-拉罗切有限公司 生物标志物在评估从动脉高血压向心力衰竭的早期转变中的用途
US9733261B2 (en) 2012-04-24 2017-08-15 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of stroke or other cerebral injury
WO2014116708A1 (en) * 2013-01-22 2014-07-31 Singulex, Inc. Endothelin in the diagnosis of cardiac disease

Also Published As

Publication number Publication date
JP6298054B2 (ja) 2018-03-20
PT2883057T (pt) 2019-03-06
JP6595641B2 (ja) 2019-10-23
RS58553B1 (sr) 2019-05-31
EP2883057B1 (en) 2018-12-05
JP2015528562A (ja) 2015-09-28
DK2883057T3 (en) 2019-03-18
EP2883057A1 (en) 2015-06-17
SI2883057T1 (sl) 2019-07-31
US11061037B2 (en) 2021-07-13
PL2883057T3 (pl) 2019-07-31
TR201902555T4 (tr) 2019-03-21
US20150219669A1 (en) 2015-08-06
US20180143208A1 (en) 2018-05-24
ES2713098T3 (es) 2019-05-17
CY1121406T1 (el) 2020-05-29
JP2018109640A (ja) 2018-07-12
LT2883057T (lt) 2019-04-25
HUE042708T2 (hu) 2019-07-29
WO2014023820A1 (en) 2014-02-13

Similar Documents

Publication Publication Date Title
Bottenus et al. 10000-fold concentration increase of the biomarker cardiac troponin I in a reducing union microfluidic chip using cationic isotachophoresis
BR112014016313A8 (pt) medições precisas de analito para tira de teste eletroquímico com base em característica(s) física(s) detectada(s) da amostra contendo o analito e parâmetros de biossensores derivados
DE602007010032D1 (de) Immunoassay mit mehreren analyten
JP2013533977A5 (hr)
JP2009501333A5 (hr)
WO2015006489A8 (en) Blood-based screen for detecting neurological diseases in primary care settings
WO2010046443A3 (en) Methods for detection and diagnosis of a bone or cartilage disorder
HRP20151023T1 (hr) Metode za detekciju protutijela na lijekove
BR112014006741A2 (pt) método para monitorização, diagnóstico e/ou prognóstico de lesão renal aguda no estágio inicial
WO2010025393A3 (en) Protein biomarkers and methods for diagnosing kawasaki disease
WO2009063840A1 (ja) エンドトキシンの濃度測定方法および濃度測定用キット
BR112014011818A2 (pt) método para realizar ensaios de quantificação
BR112015008473A2 (pt) aparelho e método para determinar a quantidade de uma proteína alvo e/ou outros tipos de biomarcadores ou analitos presentes em uma amostra
WO2016090244A3 (en) Methods and devices for performing high dynamic range immunoassays
WO2015031676A3 (en) Integrity testing of hair samples
HRP20190341T1 (hr) Dijagnosticiranje srčane insuficijencije
JP2018004657A5 (hr)
JP2012521551A5 (hr)
Hasson et al. Improving acute kidney injury diagnostic precision using biomarkers
JP2019531261A5 (hr)
WO2008131261A3 (en) Peptide biomarkers of cardiovascular disease
HRP20190801T1 (hr) Biološki biljeg za rehospitalizaciju nakon srčane insuficijencije
IN2014DN08430A (hr)
WO2012021741A3 (en) Lateral flow assays for non-diagnostic analytes
JP2015528562A5 (hr)